Bionomics Meets The FDA: Lead Drug Candidate For Social Anxiety Heads To Phase 3
Portfolio Pulse from Lara Goldstein
Bionomics Ltd. (NASDAQ:BNOX) has received support from the FDA to proceed with Phase 3 studies for its lead drug asset BNC210, aimed at treating Social Anxiety Disorder (SAD). The drug has already completed Phase 2 studies with positive results and holds a fast-track designation from the FDA. The Phase 3 clinical program is set to begin dosing in Q1 2024.
October 18, 2023 | 2:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bionomics Ltd. has received FDA approval to proceed with Phase 3 studies for its lead drug BNC210. This could potentially boost the company's stock in the short term.
The FDA's approval for Bionomics to proceed with Phase 3 studies for its lead drug BNC210 is a significant milestone for the company. This could potentially lead to increased investor confidence and a boost in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100